|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MLF2 |
Gene summary for MLF2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MLF2 | Gene ID | 8079 |
| Gene name | myeloid leukemia factor 2 | |
| Gene Alias | NTN4 | |
| Cytomap | 12p13.31 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A8K1F4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8079 | MLF2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.92e-14 | 4.50e-01 | 0.0155 |
| 8079 | MLF2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 7.30e-22 | 7.96e-01 | -0.1808 |
| 8079 | MLF2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.99e-22 | 8.64e-01 | -0.0811 |
| 8079 | MLF2 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.43e-16 | 5.78e-01 | -0.1088 |
| 8079 | MLF2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.65e-39 | 8.56e-01 | -0.1954 |
| 8079 | MLF2 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.16e-12 | 1.04e+00 | -0.2602 |
| 8079 | MLF2 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.14e-06 | 7.45e-01 | -0.2196 |
| 8079 | MLF2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 8.99e-18 | 6.64e-01 | -0.1207 |
| 8079 | MLF2 | HTA11_83_2000001011 | Human | Colorectum | SER | 9.05e-16 | 6.27e-01 | -0.1526 |
| 8079 | MLF2 | HTA11_696_2000001011 | Human | Colorectum | AD | 5.55e-21 | 6.78e-01 | -0.1464 |
| 8079 | MLF2 | HTA11_866_2000001011 | Human | Colorectum | AD | 9.23e-18 | 5.56e-01 | -0.1001 |
| 8079 | MLF2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 8.45e-28 | 8.48e-01 | -0.059 |
| 8079 | MLF2 | HTA11_2992_2000001011 | Human | Colorectum | SER | 4.03e-09 | 6.67e-01 | -0.1706 |
| 8079 | MLF2 | HTA11_5212_2000001011 | Human | Colorectum | AD | 7.70e-08 | 5.20e-01 | -0.2061 |
| 8079 | MLF2 | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.57e-05 | 5.36e-01 | -0.1462 |
| 8079 | MLF2 | HTA11_546_2000001011 | Human | Colorectum | AD | 9.90e-11 | 5.67e-01 | -0.0842 |
| 8079 | MLF2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.47e-02 | 3.36e-01 | -0.0179 |
| 8079 | MLF2 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.63e-22 | 6.48e-01 | 0.096 |
| 8079 | MLF2 | HTA11_8622_2000001021 | Human | Colorectum | SER | 5.31e-05 | 4.77e-01 | 0.0528 |
| 8079 | MLF2 | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.42e-08 | 5.10e-01 | 0.0131 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MLF2 | deletion | Frame_Shift_Del | novel | c.685delN | p.Arg229AlafsTer56 | p.R229Afs*56 | Q15773 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| MLF2 | SNV | Missense_Mutation | novel | c.682N>T | p.Pro228Ser | p.P228S | Q15773 | protein_coding | tolerated(0.3) | benign(0.018) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MLF2 | SNV | Missense_Mutation | novel | c.134N>G | p.Asp45Gly | p.D45G | Q15773 | protein_coding | deleterious(0.03) | benign(0.099) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| MLF2 | SNV | Missense_Mutation | c.520G>C | p.Asp174His | p.D174H | Q15773 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-CK-5912-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| MLF2 | SNV | Missense_Mutation | c.249N>A | p.Met83Ile | p.M83I | Q15773 | protein_coding | tolerated(0.07) | probably_damaging(0.95) | TCGA-CM-6172-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Ancillary | leucovorin | SD | |
| MLF2 | SNV | Missense_Mutation | c.512G>A | p.Arg171His | p.R171H | Q15773 | protein_coding | deleterious(0.05) | benign(0.042) | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| MLF2 | SNV | Missense_Mutation | rs745833590 | c.412N>T | p.Arg138Trp | p.R138W | Q15773 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MLF2 | insertion | Frame_Shift_Ins | novel | c.475dupG | p.Asp159GlyfsTer28 | p.D159Gfs*28 | Q15773 | protein_coding | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD | ||
| MLF2 | SNV | Missense_Mutation | novel | c.254A>C | p.Asp85Ala | p.D85A | Q15773 | protein_coding | tolerated(0.12) | benign(0.258) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| MLF2 | SNV | Missense_Mutation | rs749240926 | c.566N>T | p.Ala189Val | p.A189V | Q15773 | protein_coding | deleterious(0.04) | possibly_damaging(0.87) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |